U.S. FDA AWARDS BOTH RARE PEDIATRIC DISEASE AND ORPHAN DRUG DESIGNATIONS TO HG204, A CRISPR RNA-EDITING THERAPY, FOR THE TREATMENT OF MECP2 DUPLICATION SYNDROME

HuidaGene Therapeutics New Jersey China

Orphan Drug Designation (ODD) is a status that provides 7 years of post-approval protection and exemption from filing feesRare Pediatric Disease Designation (RPDD) qualified the Sponsor at the time of registration for a salable, transferable priority review voucher which can be used to speed up the approval process for another drug candidateHG204 is the world first CRISPR RNA-editing therapy for the treatment of MECP2 duplication syndrome granted both RPDD and ODD by the U.S. FDA
or follow us on LinkedIN at http://www.linkedin.com/company/huidagene

Logo - https://mma.prnewswire.com/media/1990114/Huidagene_Logo.jpg  

View original content:https://www.prnewswire.co.uk/news-releases/us-fda-awards-both-rare-pediatric-disease-and-orphan-drug-designations-to-hg204-a-crispr-rna-editing-therapy-for-the-treatment-of-mecp2-duplication-syndrome-301972788.html